Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS) A Phase 2/3 Randomized, Controlled, Open-Label Study of…
–
–
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1) This…
–
–
MajesTEC-7 A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide,…
–
–
A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL). DiseaseFollicular Lymphoma (FL) SummaryThe purpose of this…
–
–
This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukaemia. DiseaseFLT3 mutated Relapsed or…
–
–
A Multicenter, Multiple Expansion Cohort, Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma This is a…
–
–
87801493LYM1001 A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer DiseaseLymphoma, Non-Hodgkin SummaryThe purpose of this study is to characterize safety and…
–
–
INDEPENDENCE An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)…
–
–
AMLM26/T4 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – SNDX5613 DiseaseAcute Myeloid Leukaemia SummaryThe ALLG…
–
–
BGB11417-301 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) DiseaseCLL SummaryThe main objective of this study is to compare…
–
–
ISB 2001-101 Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma DiseaseRelapsed/Refractory Multiple Myeloma SummaryThis study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of…
–
–
IMpress_001 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) DiseaseMyelodysplastic Syndromes Acute Myeloid Leukemia SummaryThe purpose of this study is to evaluate the…
–
–
MagnetisMM-5 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) DiseaseMultiple Myeloma SummaryBrief Summary: The purpose of…
–
–
PRT2527-02 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies DiseaseAggressive B-Cell Non-Hodgkin’s Lymphoma Aggressive B-Cell NHL Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma (MCL) Richter’s Syndrome SummaryThis…
–
–
DR-01-ONC-001 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DiseaseLGLL – Large Granular Lymphocytic Leukemia Primary Cutaneous T-Cell Lymphoma – Category Primary Cutaneous CD8-Positive…
–
–
80948543LYM1001 A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) DiseaseLymphoma, Non-Hodgkin Leukemia, Lymphocytic,…
–
–
BGB-11417-103 A Study of BGB-11417 in Participants With Myeloid Malignancies DiseaseAcute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm SummaryThe study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and…
–
–
MajesTEC-9 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) DiseaseRelapsed or Refractory Multiple Myeloma SummaryThe…
–
–
SLN124-004 Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera DiseasePolycythemia Vera SummaryThis is a Phase 1/2,…
–
–
DZ2022B0002 A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) DiseaseNon-Hodgkin Lymphoma…
–
–
AMLM26/T5 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – MBG453 OR MBG453 and Azacitidine DiseaseLeukaemia…
–
–
BLOCK PCNSL (NHL32) An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma DiseaseLymphoma (non Hodgkin’s lymphoma) SummaryThe purpose of this study is…
–
–
SUCCESSOR-1 (CA057-001) A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma…
–
–
ASTX660-03 A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) DiseaseRelapsed/Refractory Peripheral T-cell Lymphoma SummaryThe primary purpose…
–
–
NHL35: ALLG-PACIFIC An open label phase 2 study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for primary mediastinal B-Cell lymphoma DiseaseB-Cell Lymphoma Summary open label phase II study of R-CHOP…
–
–
SNDX-5613-0700 A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Disease Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Mixed Lineage Acute Leukemia…
–
–
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously…
–
–
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients…
–
–
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
–
–
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
–
–
A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
–
–
- You may access new treatments, often years before they become available otherwise.
- You will make a valuable contribution to cancer research that benefits all patients.
- You will be monitored closely for side effects.
- Trials require more of your time and more paperwork than normal care. This might include visits to the hospital, phone calls, more blood tests, scans or biopsies.
- The treatment may not work.
- The treatment may cause side effects. These will vary according to the treatment being tested.
Trials have rules concerning who can take part. These are called eligibility criteria, and they vary from study to study. Examples include type and stage of blood cancer, your age, whether you have other medical problems and what previous treatment you have had.
We encourage our patients to consider clinical trials from the time of initial diagnosis. Talk to your doctor to find out if any clinical trials are available to you.
You may leave a clinical trial at any time, for any reason.
Informed consent is the process of learning about the trial before deciding to take part. The research team will explain the purpose, how long it will take, what will happen, potential risks and benefits.
If you want to participate, you will sign a form that details all of the information that has been discussed with the research team. You will keep a copy of the form. Even though you have signed the form, you have the right to leave the study at any time.
We offer access to clinical trials at our partner organisations, all based in Nedlands in Perth, Western Australia. These include the Cancer Centre at Sir Charles Gairdner Hospital, Linear Clinical Research and Hollywood Private Hospital.